These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24061647)

  • 1. The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.
    Medová M; Pochon B; Streit B; Blank-Liss W; Francica P; Stroka D; Keogh A; Aebersold DM; Blaukat A; Bladt F; Zimmer Y
    Mol Cancer Ther; 2013 Nov; 12(11):2415-24. PubMed ID: 24061647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.
    Scorsone K; Zhang L; Woodfield SE; Hicks J; Zage PE
    Invest New Drugs; 2014 Oct; 32(5):815-24. PubMed ID: 24832869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model.
    Zhan N; Michael AA; Wu K; Zeng G; Bell A; Tao J; Monga SP
    Gene Expr; 2018 May; 18(2):135-147. PubMed ID: 29409568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
    Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
    Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
    Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.
    Leiser D; Medová M; Mikami K; Nisa L; Stroka D; Blaukat A; Bladt F; Aebersold DM; Zimmer Y
    Mol Oncol; 2015 Aug; 9(7):1434-46. PubMed ID: 25933688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.
    Zimmer Y; Vaseva AV; Medová M; Streit B; Blank-Liss W; Greiner RH; Schiering N; Aebersold DM
    Cancer Lett; 2010 Mar; 289(2):228-36. PubMed ID: 19783361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
    Buchanan SG; Hendle J; Lee PS; Smith CR; Bounaud PY; Jessen KA; Tang CM; Huser NH; Felce JD; Froning KJ; Peterman MC; Aubol BE; Gessert SF; Sauder JM; Schwinn KD; Russell M; Rooney IA; Adams J; Leon BC; Do TH; Blaney JM; Sprengeler PA; Thompson DA; Smyth L; Pelletier LA; Atwell S; Holme K; Wasserman SR; Emtage S; Burley SK; Reich SH
    Mol Cancer Ther; 2009 Dec; 8(12):3181-90. PubMed ID: 19934279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
    Berthou S; Aebersold DM; Schmidt LS; Stroka D; Heigl C; Streit B; Stalder D; Gruber G; Liang C; Howlett AR; Candinas D; Greiner RH; Lipson KE; Zimmer Y
    Oncogene; 2004 Jul; 23(31):5387-93. PubMed ID: 15064724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models.
    Poliaková M; Felser A; Pierzchala K; Nuoffer JM; Aebersold DM; Zimmer Y; Zamboni N; Medová M
    FEBS J; 2019 Jul; 286(14):2692-2710. PubMed ID: 30993872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
    Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A
    Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
    Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
    Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.
    Mohyeldin MM; Akl MR; Ebrahim HY; Dragoi AM; Dykes S; Cardelli JA; El Sayed KA
    Oncotarget; 2016 May; 7(22):32247-73. PubMed ID: 27086914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma.
    Bill KL; Garnett J; Ma X; May CD; Bolshakov S; Lazar AJ; Lev DC; Pollock RE
    Lab Invest; 2015 Aug; 95(8):951-61. PubMed ID: 26006023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
    Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
    Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
    Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.
    Shin JS; Hong SW; Moon JH; Kim JS; Jung KA; Kim SM; Lee DH; Kim I; Yoon SJ; Lee CG; Choi EK; Lee JY; Kim KP; Hong YS; Lee JL; Kim B; Choi EK; Lee JS; Jin DH; Kim TW
    Invest New Drugs; 2014 Jun; 32(3):389-99. PubMed ID: 24173966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.
    Srivastava AK; Hollingshead MG; Govindharajulu JP; Covey JM; Liston D; Simpson MA; Peggins JO; Bottaro DP; Wright JJ; Kinders RJ; Doroshow JH; Parchment RE
    Mol Cancer Ther; 2018 Mar; 17(3):698-709. PubMed ID: 29444985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells.
    Humbert M; Medová M; Aebersold DM; Blaukat A; Bladt F; Fey MF; Zimmer Y; Tschan MP
    Biochem Biophys Res Commun; 2013 Feb; 431(2):264-9. PubMed ID: 23313490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.